** Drug developer BridgeBio's BBIO.O shares rise 25% to $29.29 premarket
** The FDA on Friday approved BBIO's heart disease drug Attruby
** Co's oral drug was approved to treat a rare heart condition known as transthyretin amyloid cardiomyopathy that makes it hard for the heart to pump blood
** BBIO's drug is expected to compete with Pfizer's PFE.N Vyndaqel and Vyndamax
** As of last close, BBIO down ~42% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。